Detalles de la búsqueda
1.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658856
2.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035514
3.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914866
4.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Lancet Oncol
; 18(1): 42-51, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27932068
5.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Lancet Oncol
; 17(7): 883-895, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27269741
6.
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.
Clin Trials
; 13(3): 331-7, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26542025
7.
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
Eur J Cancer
; 199: 113530, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38295556
8.
Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations.
JTO Clin Res Rep
; 4(10): 100568, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744307
9.
Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer.
Front Oncol
; 13: 1225820, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38269020
10.
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
JTO Clin Res Rep
; 4(1): 100431, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36793385
11.
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
J Clin Oncol
; 41(11): 1999-2006, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36735893
12.
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
J Immunother Cancer
; 11(3)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001909
13.
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia.
Immunotherapy
; 15(13): 1029-1044, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37465924
14.
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
J Clin Oncol
; 41(11): 1992-1998, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809080
15.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
JTO Clin Res Rep
; 4(11): 100572, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954964
16.
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Cancer
; 118(2): 493-9, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21598239
17.
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Cancer
; 118(19): 4795-800, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22437754
18.
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Front Oncol
; 12: 834761, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35402266
19.
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.
Cancers (Basel)
; 14(4)2022 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35205788
20.
Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.
Clin Lung Cancer
; 23(8): 659-669, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36266183